Exelixis (EXEL) 6 Nov 202020 Q3 Earnings call transcript

Company Profile

Participants

Susan Hubbard	Executive Vice President-Public Affairs and Investor Relations
Mike Morrissey	President and Chief Executive Officer
Chris Senner	Chief Financial Officer
Peter Lamb	Chief Scientific Officer
Gisela Schwab	Chief Medical Officer
P.J. Haley	Executive Vice President-Commercial
Asthika Goonewardene	Truist
Chi Tran	Bank of America
Peter Lawson	Barclays
Andy Hsieh	William Blair
Leo Wallen	Cowen
Michael Schmidt	Guggenheim
Kennen MacKay	RBC Capital Markets
Duane Kailas	Needham & Company
Stephen Willey	Stifel
Charlie Ferranti	Goldman Sachs

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Exelixis’ Third Quarter 2020 Financial Results Conference Call. My name is Holly, and I will be your operator for today.

As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. ahead. go Please

Susan Hubbard

and the Holly call. all joining for Thank third thank quarter for Exelixis’ conference XXXX us you, you financial results

the Joining development P.J. Chief will corporate, are quarter CEO; me September Peter Commercial, Lamb, third our call who our Scientific Officer; progress Executive on and Officer; financial, XX, Vice Chief President of and Chief Mike Medical our Chris our ended Officer; commercial together Financial Morrissey, our for review our and Gisela Haley, Schwab, XXXX Senner, XXXX. today’s President

for we results. During the principles. well as refer call press on of GAAP not measures deriving using calculated tables to as reasons for refer to today, release, measures accounting such will accepted non-GAAP website from to is our posted explanation our financial measures generally which these today’s according an Please our

presentation, identify with under I course developments Mike. course, product commercialization heading commercials, to and regarding the and strategic costs events trials, related and of Actual over call the to the and time review in verbally conducting uncertainties materially. results dependence clinical expressed level commercial forward-looking development, includes which, financial writing making will competition, or associated about the During of could, differ discovery, company to events turn on without This the factors results applicable statements by important collaboration to from this that, including our the cause development, And limitation, partners of materially compliance will processes, regulatory, actual risks future discovery, company. those differ and with success, product statements business approval activity. today, development the regulatory regulatory product performance market with we future requirements, and be the documents could to regarding of time SEC, we We the refer Factors, file matters. Risk that from with you the possible and

Mike Morrissey

milestones. continued Thank all the right. of thanks a of built trial was for our and quarter, positive and Please business regulatory and potential results to growth for our an release issued press for us results third mission evaluating to highlight was we key opportunities The revenue accelerate advance combination Phase the you, hour CheckMate quarter of everyone joining first-line third on to the of and in commercial with presentation cabo/nivo has corporate see new components list ago variety ESMO XXXX pivotal as the the foundation the the -XER, Susan financial in the from All critical Exelixis that X today. quarter accomplishments. extensive of our developments XXXX an call the cabozantinib in RCC.

The of application in overall of significant prior Exelixis accepted of extended duration response, February United in We’re States, commercial discontinuation The notably low excited come a should life the compelling compared survival the has tolerability cabo/nivo review doublet, both with activity XXXX. to the and of PDUFA of survival sunitinib. is quality response the rates to with objective improvement the a progression-free doubling health-related and our and the XX, FDA highlight rate improvements and organization to improved sooner. launch-ready with date approval granted

accurate. agents. if and large market When from exit are RCC benefit of could billion untreated that our size focus a data TKI and RCC a urgency in market-leading RCC best-in-class the reinforced run are single a of consistent -XER and together, Our indicates ESMO cabo annualized combination the number of duration long IO, patient research, XXXX revenues viewed to driven expect represents rate and these $X.X modeling previously which first-line the doublet project potential of that of PFS feedback observed with U.S. recent population from are by cabo/nivo two at the the doubling by assumptions we patients and with

remains the growth as RCC top Our first-line next our priority commercial opportunity cabozantinib. for

cosmic These while with XXX, as as key success combinations presented continue make for with progress The meetings potential enrolling advancing XXX, been year cabozantinib cabo’s coupled indications. XXX, We a as highlights XXX three and the TKI indications. initiating activities and progress cabo/IO well oncology four play this the may of bladder tolerability CONTACT X read new pivotal backbone. of and various in in encouraging CheckMate made new pivotal Notable the XXXX, utility cancers development trials to combination in trials, potential of global additional important of clinical has Phase with ESCO including throughout atezolizumab and in as compelling differentiated discovery liver, lung QX trials part at can and current data trial signals program. through important cabozantinib role in early unique provide -XER, prostate, efficacy and for and

in significant early stage progress make pipeline. Exelixis to growing Finally, our continues

to broad XLXXX potential to into has improved initial our more clinical We advance an early profile share a more risk years with with to XX a We profile TKI excited our and inhibition of of programs. We aim cabo’s the typical multi-targeted XXXX. improved accelerated early XLXXX characterization, development target in detail and overall phenocopies combination will anticipate apply to next-gen clinical validates that half-life. discovery cabo which plus into efforts build ICI development demonstrate its and are the cohorts a user-friendly stage pharmacokinetic clinical to substantially that experience compared move to plan full

to important a Beyond XLXXX, our efforts nicely continues new with number stage to in advance of growing early ADCs. pipeline in presence collaborations our reinforce discovery internal

of proud the by file our team four to continue of to business over internal our efforts the forward the six and incredibly times. displayed to as and Exelixis work a drive months result these next our new we partners. entire up INDs as discovery I’m expect during commitment a focus We of challenging

will who over Chris, provide that, with an on results. I’ll financial So QX to update call our turn the

Chris Senner

Thanks, Mike.

million. a reported by $XXX.X Total the included of revenues XXXX, negatively revenues For of franchise Genentech. for quarter demand impacted quarter decline $XXX.X product $XX.X third and total Total in product inventory. by of Net XXXX revenues million collaboration lower the and cabozantinib million. in Takeda wholesale were the net Ipsen, revenues revenues company also the included third in from revenues quarter of

million total which XXXX. related investments our of emerging third for $X a basic from per basis. million over effect. income expenses increase The ended $XX.X development and the the driver increases excludes quarter for operating from of the Our second third of quarter the net our also $XXX.X income in licensing in the income taxes million million pipeline. cabozantinib net of primary reported compared $XX.X operating existing with the activities, taxes expense per of quarter The company of for compared third the compensation of second and income billion. or clinical quarter by expense loss of the million net income for reported was stock-based quarter of our was Cash $XXX.X provision was XXXX $X.XX share for expense total a million approximately $XX.X to of company XXXX in $XX GAAP net XXXX. in expenses, tax share XXXX. increased to the quarter to primarily million of associated to were the benefit $XX million non-GAAP or on a and Provision related of continuing benefit Non-GAAP milestones compensation September XX, approximately business and and new the investments impact stock-based was trial fees for $X.X fully XXXX expenses R&D and $X.XX for diluted

Now, XXXX turning financial to fiscal our year guidance.

provided we business this the We year in second guidance XXXX. to have updated the in changes to half reflect earlier financial of the our

expenses are higher and expected which and $XXX expenses due primarily the be Selling, are approximately rate now are related expect and stock-based our turn the We and incremental range higher licensing new which in and the guidance in $XXX $XXX to range and to million general related be million. in expected non-cash of billion. impact to in million million, milestone be $XX non-cash in expect $XXX over of due million due range projecting million. maintaining Peter. expenses XX%. does million net And R&D expected and revenues. to product goods guidance, of to to of includes is the revenues $X.X $XXX Research expected business of of and forecasted range Guidance it which range billion personnel product to range of And tax activities. to increasing is million. X% cash we’re approximately $X.X costs be are total This sold to decreasing; primarily Cost million, the and million approximately expenses, the expenses increasing the reimbursement $XXX the compensation $XX development and to of of to potential finally, $XXX I’ll be and be the in XXXX is $XXX that, investments with to development effective are of include are revenues XX% compensation Net we not be includes in administrative stock-based call and related to revenues. for

Peter Lamb

opportunity efforts. this for thank program Thanks, and discovery early Chris. our stage of and and I’m employees. particularly of happy advance to members the the continuing make protocols an Aurigene team data Invenra, of to this our discovery to our like Work at has work see development preclinical of Alameda to take our partners, all continuing to Work update has continued making to ongoing It laboratories and as pipeline and exciting CROs. on progress preclinical is network protect is happen. at our development stringent discovery at our on health discovery following I’d to expansion Iconic, provide an flow we’re

four opportunity next we the up to have INDs file a now As to result, in six months. the

our with our Iconic in a meetings. we quarter, which of the recently also EORTC-NCI-AACR VEGFR, will we with for presented the trials could Aurigene CDKX from action. the will next on we which to XLXXX, XBXXX, laboratories from refer MER our TKI AXL, TAM and Early forward. compound AURXXX recent as tissue for We could focused novel currently XLXXX, ADC ICON-X next-generation going inhibitor Phase internal XLXXX; at mechanism kinase that INDs second data X our year, from collaboration, file MET, in and inhibitor, refer from factor-targeting collaboration, Aurigene is collaboration to a INDs we going our file forward, This the

cells checkpoint the targeted plan data on In including major same I therapy particular, of tumors factor-targeting and the on In on and are ADC been and at multi-immune ADC overexpressed presented We AXL variety MER therapy, drives immune recent recap scientific the in activation widely second tumor data angiogenesis. on compound tumor activation addition, their Conference. cell also MET year. next survival blockade. on and Aurigene XLXXX Both to combination. the key meeting, tumor meetings with respect and Cabozantinib World were of microenvironment. the gained is chemotherapy, CDKX in data both at build inhibitor the activation presented XLXXX, VEGFRX angiogenic various and types RTKs four their to Both cells Iconic suppression. metastasis. MET, inhibitor Aurigene microenvironment tumor will interventions, present MER, XPXXX clinical in XLXXX in as linked and AXL to in tissue the the the XLXXX the RTKs, expressed invasion, from of multiple All single therapeutic of presentation. understanding in solid on are endothelium VEGFRX, from growth, AXL a the which increasingly we’ve potent to to data expressed is that and tumor the and cabozantinib, radiation has a and expressed in-depth intended are agent some the upregulation promotes tumor and MET of the immune a the and and activity at and resistance

the phenotype. of in of response tumor-associated dendritic results activity Upregulation in model PD-LX promotes MDSC in a compound MET, washout X was extended a This very with activation single tumor-bearing Phase MER blockade which tumors. half-life a hours, shows neutrophils in activation drive in of for the active, AUC macrophages patients its XLXXX the in clinical with in assays tested and a VEGFRX but while a proliferation for mirroring shorter increases inhibition Phase an is cells. two relatively a In the and formulations dependent PD-X that’s with model in XX accumulation combination of is macrophage X activity XLXXX cohorts but MER Arraignment combination of a terminal significantly XX immune antibody. occurs is those XLXXX of in activity and Over the half-life model to significantly of in Cabozantinib from assuming cabozantinib. resistance. Overall, We’ve it’s well-tolerated the XLXXX results and cellular suppressive the MET busy similar colon further refractory single to inhibition significantly inhibition doses lung the and with tolerated. a For between cabozantinib, optimizing In promotes checkpoint notably initial install profile having survival maintaining and preclinical suppressive XX vitro four half-life inhibits in with RTKs example, suggesting PD-X AXL agent hours, in withdrawn. and mice go XLXXX antigen comfortable or highly not the syngeneic Treg when a synergistic it’s antibody VEGFRX of of and perspective inhibitor XLXXX on activation to MET pharmacokinetic did XLXXX target also advanced immune subset xenograft and survival, cabozantinib. hours profile profile PD-X tumors cabozantinib and and models antibodies terminal to improvement has AXL AXL CTXX Xb shorter VEGFRX, quarter who survival, identify with been target while are multiple period vehicle. in with a number for this clinical clinics, terminal of drug in be being Phase promising about MX hour and by XLXXX that business on All trial half-life. Cmax have contrast, profile. and to solid presentation the in clinical and than trials. The cabozantinib. revenues. discussions. PD-X Activation the carcinoma compared in alone XX to activity drug relative a data to vitro meets the to improved mice that’s had activities resulted to treatments combination. biochemical potent in a in and dosing half-life. agent development show a can’t antibody antibodies and shorter The profound of gets in with tissue advancing well to in with you were XLXXX activity combination Oral XLXXX, consistent PD-X a MET and of cabozantinib improve as

until see which molecule recently and opportunities we small and assess We address compelling and to to forward clear continue these path programs. new technologies. a collaborations payload the We in develop an be a most both by what with stage first would intend us to our broad on payloads using spectrum the clinic, collaboration from These targeting additional would to appropriate these forward the updates to they which matched reach in subject follow the I’ll We antigens, look XBXXX. of to call with over a now the types come tumor on to IND filing a Redwood collaborations, develop find scientifically and we – effectively biologic for we clinical specifically pipeline when could the with their on emphasis Iconic space, for That’s to respective providing of develop turn commercialize and with site-specific near conjugation a given to fruition. indication. occur announced tumor Gisela. NBE-Therapeutics on discussions Catalent’s ADCs Through ADCs of BD novel clinical our selected future. ADC as

Gisela Schwab

We’ve for in an positive and cabozantinib CheckMate to lot of BMS cabozantinib development made results Exelixis. late were regulatory in pleased you, progress with towards April first-line new progress on since Thank I’ll XLXXX, combination the by our start program top-line Peter. announced nivolumab and RCC, and IND. a moving provide compounds I’m update and on -XER.

recall, As sunitinib. over reduction risk three endpoints, sunitinib objective the PFS XX% a doubling overall for improvement comparator, a demonstrated benefit significant survival in a significant you all compared to the study in rate a death and and of efficacy including of response the with

were by XX and results Choueiri symposium milligrams Camilla at of Dr. the discontinuation improved a with low and generally virtual of favorably, Parker. maintaining compared Toni Conference combination was quality the by life dr. and Detailed the Presidential while to study in ESMO the recent nivolumab Additionally, presented at cabozantinib of rate, associated sunitinib. daily discussed well-tolerated,

On our progress great with and results made we’ve of the and trial, regulatory together basis the partners the EMS Takeda. from Ipsen

the concurrently signed filings supplemental the in for Australia, the Pharmaceuticals, date Europe just with a submission, Further of with have filing a few for EMA and review NDA the September Concurrently the and Canada, together progress. August has sNDAs have XXXX. concurrent XXXX. the cabozantinib completed on partner validated cabozantinib also in We And international program many of for rapid for February have recently in the BLA and have of completed been BMS’s accomplished, submission the days order. with priority States in -XER, filing more including supplemental United continues ago, ongoing BMS of and to the States submission X CheckMate our PDUFA XX, also advanced Japan. the and filing Brazil, the short and to FDA at also Switzerland, in accepted United Takeda phase to on XX combination Ono besides which Ipsen progress follow RCC the submissions nivolumab of make announced with

studies, results level. where our efficient enrollment for COSMIC-XXX, top-line have these completed as shared. track on COSMIC-XXX or a on trials previously and nearing and these are we execution continued We the have of COSMIC-XXX And global COSMIC-XXX full are either for

globally. under X enrolling and to CONTACT studies start and Roche. in three are program phase we now have up also been collaboration Importantly, X all with phase able screening patients the three the trials

with and have despite and due XLXXX progress able the I’ll turn thrilled conditions and new pick teams to global to now times clinical level I’m and to execution rep by progress progress our the the around and to due teams, global the who the conditions challenging around make in significant program times [ph] cabozantinib quarter, the of projects. program the been challenging on regular pandemic. this IND world, together on back the both Looking on world the progress despite the our of

in management Peter is with tyrosine a MER AXL, in target This next with pharmacokinetic half-life. XLXXX targets to cabozantinib but has tolerability efficacy detail, of VEGFR associated shorter rapid designed the while kinase and been for MET, that flexible profile is As inhibition similar a profile potent key our cabozantinib, inhibitor the allow with of and generation expected is profile. described maintaining

ongoing of already goal the that a Our phase while study dosing. with of been that’s phase study atezolizumab accomplished has part the X with single-agent pharmacokinetic confirmed shorter combination of evaluation a designing molecule recently and parallel completing we’ve in a half-life the the Xb begun

to We are of late combination settings of for interest inhibitor and XLXXX stages and other pursue various intend planning development checkpoint well of the comprehensive lines with established potential various also therapy interest. the as of a combination broad duplets new new in promising comprehensive tumor including and as inhibitors combinations, across partners checkpoint program indications, XLXXX in evaluation of and

in a to settings build combinations, and tumor see deep experience need first extensive opportunities strategies for for solid indications and market TKIs as have expand of planned We therapeutic the lines development. unmet high foundation XLXXX to with for therapy including potential accelerated indications with we for and many cabozantinib, and potential on and

standards the in being with with and or strategies approved expanded novel develop to cabozantinib cabo’s experience of beyond our goal moving tumors, developed care new and clinical combinations. Second, building is the

are as may inhibitors focusing as expanding goal that to data-driven XLXXX variety programs. to highly drives they’re word start indications that opportunities due experience in I’ll clinical IND compounds. of should late-stage improved dose potentially stage combination This immuno-oncology are with potential and move the XLXXX years it’s of trials finally, for to rapidly RTK advantages our profile cohorts also more experience have versus in XX distinct the as offer half-life. checkpoint footprint, inhibition XLXXX settings with as chemically with utility be and differentiation candidates. through molecule; cooperative the new confident advancing IO tumor investigating late the into cabozantinib, that activity to and tolerability types. on half-life profile the XXXX, shorter and and broad options shorter space, with Xb development we understanding ranging risk in phase in brief we accessible across soon potentially of with enthusiasm a we likely on the exploring And success might with expansion our Based potentially and support outcomes to view a improved greatly can excitement typical improve our ultimately close Third, potentially XLXXX where being regarding white treatment the development well. around early-stage approaches new and TKI

that ADC few candidates reach end as the XLXXX by discovered inhibitor has an Aurigene, IND are that IND our are of over in filing towards first a I’ll filing the that, partner will been months. or making good before IND And also working and by with product for P.J. been hand We to biologic call additional next the discovered year as XBXXX candidate, for has Iconic. CDKX progress ICON-X, well and

P.J. Haley

where Thank growth. as first-line the program to that -XER additional data by we to approval built further as return anticipate discuss continues Exelixis. the momentum will cancer cabo. important SUTENT share agent a revenue CABOMETYX segments, QX presentations stable in RCC volume the one QX. cabo foundation business CABOMETYX, by HCC. into prescribed our CABOMETYX of VOTRIENT driven pleased the key you, data. head in CABOMETYX remain number XX% brand in and discuss was TKI. X% data basket year QX -XER RCC in declined TKI our TRx impact potential brand significant the remained to development to to stable of to market the time, subsequently, relative in X% according while we both positioned and single with by that the for forward, – the TRx the could are kidney INLYTA, and Gisela. data in combination at looking in be which will we QX. launch the opportunity robust oral first same pleased I’m to as franchise volume readouts we further indications share I generate CABOMETYX QX the relative CABOMETYX relative and at TRx The QX, continue to by in provides to declined IQVIA, build combination in XX% XXXX, for we be transformative strong as QX upon RCC, market of other

the with with well-received patients risk used combination data research market. with large U.S. XX,XXX the combination us conducted. first-line As our franchise on focus market first-line are future in these growth RCC CABOMETYX ICI opportunity broad the ICI with among and that therapy was in results grow brand potential may I presidential setting. mentioned, demonstrating duration The -XER the in were profile is at the in of approval first the share pending market of the therapy the to eligible we presentation of increase this cabozantinib according first-line impact consisting provide by XX% is were excited opportunity and approximately extremely in we’ve that nivo of high session setting the and XX% XXXX by the a ICI-TKI data the CheckMate for constitute CABOMETYX squarely market KOLs conference We combinations the the and recent and the presentations widely of of data, groups ESMO believe the across to clinical and line. outcome most study. regulatory -XER in

ago. CABOMETYX second-line was market. over XX% constitute combinations approved ICI of in the Additionally, four RCC approximately RCC years

other the this physicians on TKI we very educate two has that time, ORR patients brand speaks have equity experience versus so currently in and CABOMETYX doubling the Exelixis’ in from RCC the viewed to and available. launches the opportunity the the therapies During with developed more look which median prior setting. therapy first-line as strong itself, team strength for data combination -XER superior differentiation the versus RCC. post-approval, and of of with successful it sunitinib, -XER survival best-in-class to to is and progression-free has strong The us a overall provides The forward data opportunity benefit significant IO in survival

the trial the primary broad clinical Importantly, used in or status in patients a progression, majority of marketplace. IMDC rate regardless observed risk supporting patient low of were the benefits in in vast resulting subtype of

optimized line, our a a prescriber starting nivo share quality ready in the has granted. progressing in familiarity time as compelling dose as XX approved. eligible daily in our research. when addition, of monotherapy. in together, setting as stand from low and traction our we the we can like which combination life, the safety the to and as physicians leverage CABOMETYX preparation laser combination favorable same profile both customers and based therapy and been and all for both and cabo a approval into to with treatment will launch of will notable of of patients live quickly of tolerability discontinuation is cabo In cabo the best-in-class with data FDA the TKI we been milligrams with yielded both taken believe along positive academic the rate combination be compelling in with efficacy groups well-established a immune across the RCC. CheckMate the present on along from the -XER broad data on with feedback CABOMETYX positioning like and first focused community and success be strong inhibitor, CheckMate in extremely engage we as launch soon safety oncologists that combination highly opportunity team there has gain to is and appropriate second the At virtual ICI customers -XER settings first-line line checkpoint risk story continue nivolumab our enable RCC, to a in and motivating to clinical

and build other to our market market inhibitors our immune potential The -XER remains in program in positions, every potential. XX day contingent significantly of to course, of that, or progression-free investigator in per total which not prostate turn combinations the share duration to was significant the the of of in cabo/nivo/ipi, into combination. evaluating franchise I’ll believe the and our any percentage cabo of as patients, that commercial of was marketplace. we in incremental taken think run triplet revenue motivated future duration development bring with median any a pointing and population and indications, patient potential included checkpoint we ICI continue clinical second-line, modeling the COSMIC-XXX, We provides new in Mike. therapy include the over other CABOMETYX share months towards and monotherapy. potential second-line does assumptions, RCC insights deal totality first-line take a $X.X looking forward. five the cabo/nivo lung for as and median this the over the the of about Furthermore, of cabo its growth the XX well. call across data from data first-line the partners. over CABOMETYX the and vector all benefit U.S. this the in increase CABOMETYX very business moves to We continue development -XER, as for cabozantinib to about be projection XXXX. duration forward There’s And cabozantinib compete to very DTC, focused by back by along is on in end excited to study, survival in broadly CABOMETYX RCC, a maximize RCC we of the combination it potential and multiple to with excited setting building the team be business combination a advances. look response capture positions to months high of highly with momentum billion such program, is HCC, together, eligible potential beyond therapy as than to to in and forward the may were with cabo the the and grow readouts. indications great duration setting to this revenue the upon longer rate different of as

Mike Morrissey

P.J. All right. thanks,

the As while new year we outlined trials, activities important at lifecycle pipeline cabo is of from JPMorgan to months. readouts in grow themes indications to a all face been seen acknowledge potential business as the from COVID-XX in today’s the all the our building assets. three with call. advance of January, and across severity pandemic progress last key risk pandemic. of the -XER, XXXX the and portfolio the continue transitional we for over achievement year we’ve a several time, has by should diversified business, XXXX our combinations, of Unfortunately, a we close our at significant I’ll date, as in ongoing pivotal continue Exelixis sadly components to and reiterating management navigate same like and to

be XXXX the accelerate of for project we revenue the to First, transformational and approval year on cabo a franchise growth a cabozantinib. size we for to as -XER expect based with expect U.S. XXXX the we long PFS our RCC first-line for rate billion $X.X in exit to is annualized -XER, the RCC a in and market accurate. if run duration of modeling Exelixis

MET, more Second, inhibitor AXL, next-gen broadly to significant we’re XLXXX new variety of combination a and MER multitalented represents and opportunity it as IO the existing indications clinical expand the tumor into strategies. VEGFR, with encouraged backbones solid by user-friendly with half-life and a

updating continues commercialize, their and in team our develop molecule everyone majority team for small for future. by for each you Exelixis cancer the working to The that to our more cancer months portfolio even work energy. in of seven the and Third, support and more demands the of home from and effective making Thank helping with interest to including as our efforts in and been medicines of I’m we and has proud meet as for forward thanking call your on to appear third progress the quarter medicines, need the business modalities in at our we incredibly now, close patients I’ll to our and under than Exelixis quarter. treat that difficult cancer in continues potential biological challenging aggressively generation to We you are more day generation and continued of the Exelixis get open questions. teamwork, increase advancing investigating Exelixis conditions the one both to more next with happy great and patients success look more therapies. next count discover, and tumors. better to say expertise, for of diverse every entire now we’re

Operator

[Operator question going first Asthika you. Thank with come of Our from Goonewardene Truist. line the Instructions] is to

Asthika Goonewardene

would negatives, of you maybe, new But there. about lot as outside, cash. accelerate think data what understand PD-X we’re guys nice just again. we to wondering, a to the kinds you you in they glimpse maybe, of of agent that I would may, first combo billion have development those chunk wondering dose I well. totally expansion? few to then a That’s taking single I’m that to. opportunity actions or and those quite acquisitions about business maybe, mechanisms it’s activity How maybe then for could PD-X you quarter us makes mentioned for vaccines of what you? be the when you A Mike, a sense from and for showed would mechanisms on And bit development more And going a Peter, ask, $X.X get underplay of if Thanks have guys. the XXXX? my about be guys. Gisela, and a if lot, I little helpful. us still to Hi, to besides Thanks have XXX, nice and think can tell be focused up a CTLA-X questions, of color to deal further, do was you excited that licensing see

Mike Morrissey

right. All

you a there’s on Peter Asthika, there. we and start XXX? to there? don’t Why want Gisela, with start Gisela lot

Gisela Schwab

as we we or to presenting certainly stage And half-life data, that has see XX was question in the to phase present get a Sure, mature around it absolutely. the it And or you we that for that of just data, when we’ll showed that have included to question. the and XXXX. Thank further already is designed. about And when hours course, know bit publishing even the behaving And recent when Peter on it. so. data a studies of data hoped molecule pharmacokinetic hoping and of late at little are the start we data. look presentation and referred shorter regarding for a first data, before was the we do was X shown the get

– a forward we make move we certainly, you’ll can decisions And in so as see little bit that do, you earlier direction. us and as

Peter Lamb

in take mean, upon the opportunity there on mean, have as the essentially from think Yes. they additional double, IO question a beyond cytokines, to POC kinds combination we to savings. be your be all good PD-X, commented, already I I of the XLXXX indication even with there’s continue the which partners, novel PDL-X, I broad could, CTLAX with IO being oldest, or clinical modalities I’ll be with, might combine to potentially – you end and just at even triplets checkpoint cabozantinib. XLXXX Obviously, of inhibitors, development on we’ll which look agents a could appropriate of up the depending be they have

Mike Morrissey

Peter. Okay, great. Thanks, Gisela. Thank you,

kind either said expand BD previously, with the for. pretty I detail. of kind obvious quarter we’re good importance using our with we down have certainly have, of the did those – of Obviously, we’re to development on we’ll get go line-up compounds if well. this with as as deals and preclinical those business side, of and/or as feeling The whole focused XXX activities, Catalent’s on forward we we the combining announce possible, about coming NBE on a when talk of we for side, a roster, deals more number the to think, that pursuing. We very done. a clinical Asthika, ADC pipeline we’re potential pipe, the of done, looking in if those activity get

we’re in of right team effort investments the the right the value, that we time assets right at right for terms opportunity full So, to there’s right. a how focused make here sure it’s the make and for lots of

– really to speed. we but – full network at getting our those and the going very collaborations about additions the we’re excited looking to So of that have forward collaborators recent to tracking and

Asthika Goonewardene

guys. lot, a Thanks Great.

Mike Morrissey

You bet.

Operator

you. Thank

the from Jason America. next Gerberry of of bank Our with line question is going to come

Chi Tran

Jason. This me there’s the our have evening, Chi that in XX% talk talk questions. afternoon. is that, first these IO/IO renal, is to did IO/TKI use of say next line? ICI may IO/IO versus where taking an one for The is Good patients, do a on they in combo? or who about you you XX% received for TKI Thanks maybe, Hi. retreatment, everyone. about ICI the guess they an receive monotherapy for between in I combo’ed patients, IO and were IO/TKI second about Good curious, and frontline the split have were

P.J. Haley

chi. Thanks I’ll question. Hi, for that. Yes. This take P.J. is the

is and of think and I is per as question, So, we broad. share of combinations, RCC, the current very line. of looking IO your second market large in in XX% sort the opportunities -XER the mentioned, at

and market, a in impact, data setting, that’s in -XER see a – large So, right. IQVIA place and there’s to that’s brand about all what the is XX% combinations that’s the first-line is of for IO And account done. and the we study this the larger population, which according

first-line was uptake total So, taking is the according we data positive. about the would IO/TKI IO that on large I’m brand agents. There’s anticipate really kind of first-line and referring a done coming point, that -XER of again, those very is a of real market second-line think certainly, feedback we’ve market IO/TKI. I And is just and what is to the research quite the really this that’s impact. us excites IO/IO. of this setting. of physicians is XX% mix after variety XX%, number And see about the to of there. data no and strong the pattern with but a I The you at of XX%, combinations,

months’ regards And in particularly PFS investigator, a we’ll the drive we When of I with of As of and duration aspect for safety of share. there response first-line market think mentioned duration the setting study. we tolerability, and quality efficacy lot look think business. a life data, opportunity therapy in to can significant will by that the data, the the mentioned really also we significant -XER of XX really XX at and be as I months have

longer therapy duration in see what of that that certainly So, than much monotherapy. believe we be long we will CABOMETYX –

Chi Tran

potential so, I Awesome. be like the see to see in now further reach, other filling line, for guess, see of it expand up IO/TKI keep going by XX%. seems approval to added -XER frontline bit quarter we’re pushing where you do assignment that the IO/TKI for opportunity potentially to there’s XX%, waiting can setting? to IO/TKI potential a the would front be do at and every or you bit back right

P.J. Haley

And Yes. we I broad. potential Chi. question, see as of Yes. mentioned, that Great kind

that’s profile we’re view best-in-class getting the being So, feedback competitive and as we our the XX% IO/TKI, very there. being certainly and

the We share we share we XX% could segments, And compelling that those broadly of physicians in as So, that share expand lot the can TKI the is our we in data. segment. take to believe in well think certainly we monotherapy, and from as we to as we think other IO/IO have segment patients. can take on the opportunity because benefit segments it, steal market certainly, the all this educate really

Chi Tran

that, when on any guess a from data color is guys provide last second-line expect maybe, Thank indications. cohorts update you. I me if particular these your we for can can COSMIC-XXX, one in two and potentially your on you and Awesome. your next progress prostate

Mike Morrissey

want Gisela, you do take to that one?

Gisela Schwab

cohort cabozantinib pre-treated early and toward population, path, that rate non-small and you non-small understand of Thank planning but cell disease CRPC XX% well. involved lung for And CRPC Absolutely. X combination, following atezolizumab data particular have we These have response additionally to mature, that be with and a we address response and lung it’s happy rate long ASCO duration cohort fully the dependent FDA, study. year, control for will in a likewise CRPC upon indication a cancer approval saw XXX the rates initial and activity are had encouraging in you. where of both for and lung the in patients interactions rate question for indication, at Thanks when also of and accelerated in XX%. is data for potential additional cohort CRPC towards and presented showing these the cohorts in and the there also checkpoint I’d cell the And a as in the with cohorts, both up XX% for we the data in and cohort, then, X fully control inhibitor for and that disease are course, X would now to ask, mature populations. COSMIC-XXX we

lung inhibitor, cohort updates patient to forward the both indications So, to and we just for certainly, on cohorts pretreated look providing these following the a complete population. available cell as and cancer up non-small and checkpoint they become

We patients also the other this in XX study single completing are well. cohort and agent as with enrollment

forward nicely data. So, mature advanced more to look this we very and has

Chi Tran

one happen? interaction just did follow-up from FDA the that you initial interaction When said, had When maybe, with prostate And me. quick on the cohort you X data.

Gisela Schwab

based various terms encouraging they encouraging observations have calls, of that in discussed that initial we’ve We so, seen while objective discussed rates. response patients so upon results on conference happened a when X in the we cohort or very first the back the XX where

So that’s we a feedback. encouraging initial that while received back and then

Chi Tran

Thank it. you. Got

Gisela Schwab

Chi. Thanks,

Operator

question is of next Peter the come to our And Lawson going from with Barclays. line

Peter Lawson

my for inventory or and low this setting, taking just from just whether it Hey, out that thanks questions. revenues, demand, academia quarter? came community anything on you was what if the around could break

P.J. Haley

differences regards kind with or system, being academic that’s in regards just really, still RCC visits the any Certainly, impacts we’re there. sort see the in and from seeing we to with of demand, think the TKIs P.J. community with cetera. market dynamic broad some down, patient a in various what down do didn’t really healthcare the and basket We’ll market et is this there it’s we entire COVID to to quarter regards to is follow-ups, the I approximately script of X%. a of Yes, I there, And saw referred were what – in

something also products with we reporting certainly well. saw to earnings the – So, saw and market, think in broadly it regards that’s in as the I those

Chris Senner

Chris. is Peter, Yes, this

rest franchise for higher is reporting about to slightly related that inventory the probably what this P.J. kind $XX we $X And of to about – cabozantinib a million. the is which then was sequential a gross of or three quarter-over-quarter half so was to talking is of to demand, about million down related from and reported remaining and net. quarter revenue About about. So, correlates with perspective, related

Peter Lawson

could drive run we think then revenues acceleration you. just kind of any as happening be color then Thank those Great. about what what and helps around QX, And in October?

Mike Morrissey

not and driver for that script. quarter And talk the Mike. Obviously, in the is growth it’s appropriate biggest as approval talked to the this Peter, launch, we probably XX-hour about Yes. early. revenue about

get to out data about there team ready driver stuff. to data the prescribers letter skilled excited we’re that’s roll once that’s on the very call physicians, the the and today. So, and/or But certainly we certainly potential, big and big the educate is for the message the and and and get prepared and the

Peter Lawson

around HCC, I declining then since any if find well. that Great. just And as around growth, was anything

Mike Morrissey

Yes.

P.J. Haley

HCC again. say And basically as quick seen looking obviously as Hi, that and the uptake with positive, that well out XXX to also we’re forward, the we’ve in and Peter. HCC. in in stable combination in first-line bev/atezo in such One in regimen for forward HCC, be potentially driven first that approval significant, reading has broadly it’s cabo/atezo, were atezo HCC. look bodes study for is we’ll setting And into should P.J. combination the line thing businesses in QX, more we It’s the in is HCC. moving another personally, QX the really what therapy data IO

we to the current in share market kind CABOMETYX so then second So, forward dynamic take that to positioned kind opens sort is would the HCC RCC, HCC. and study seen anticipate celestial in think IO they moves beyond the as from second patients whereas in we of then in progress that And of label occupied that well look we’ve of utilization. line or TKI line longer-term, line in IO a as more data therapy in for our in more that we of up XX% second what of similar

Peter Lawson

much Great. the Thanks so for detail.

Gisela Schwab

You bet, Peter. Thank you.

Operator

come Andy the will question from line with Hsieh of next our And William Blair.

Andy Hsieh

everybody Okay. Thanks I at my Exelixis. well and question hope taking for doing is

basically question at I presented triple regarding meeting. have data a So, the

So, higher more actual. exception and against tenfold I potency think [indiscernible] about that there similarities with differences the the are is there like

for what into that and XXX, clinical thinking fact also COSMIC-XXX from for development in-house out stage I optimize the chose much of Gisela of accelerated So, the specific question year. that really of kind is thinking about first kind relevance, specifically you question next the kind peek you And but things have the the you of about how Gisela, why that in just derived development development guess, kind picture you’re that of advancing Peter into to for for or similarities, XXX. can asset given path late and the target laying bigger

Gisela Schwab

Yes.

Peter Lamb

so, Andy. feel endeavor. We for and questions Thanks the

I pretty the from was AXL much potent XXX presentation one retained if with meeting feature, so got MET, VEGFRX and profile wrinkle cabo to the XLXXX. triple There target So, is against was the in MER was max the VEGFRX. more with message slight and there against of potencies where, think you’ve against and aim cabo, the the that potent the retain that and potent we of

plays nicely well. vivo in in I as quite think that the setting out

think, more was correctly I optimize to in wanted an AXL on specifically And it out didn’t bit say, enough. emerging potent. I turned interest of we as primary that giving it not a was a significantly it’s but sure go have definitely you be optimization. We potent being offline. mean, tumors target the retaining of that a something was solid driver into, of many a and we lot that may target It them pharmacokinetic whilst really potency. profile shorter indications

Susan Hubbard

to want take the do Okay. question? And of the Gisela, second you part

Gisela Schwab

for Thanks you. the Thank question.

forward? or drive the was we’ve described, course, how half-life and can while shorter retaining that key with have we be very within. this XLXXX, activity seen I applied a question encouraging differentiated development a around of for inhibition XXX, from question, as So, things is profile a it love and path is has the think we’ve the Peter can and what profile as we and learned suggests and and we COSMIC-XXX can what to target learned the that product learn cabozantinib

So, and with combination. cabozantinib of as we with lots a have single experience agent that, certainly,

that in COSMIC-XXX, to can looking we we’ve we’re build line that experience current two anything – replace broadly on indications when we viewing also including way we the of about combination bear think experience as costs and also not indication. outside with rather really learned cabozantinib everything opportunity the comprised specific is that so existing build upon And for the cabozantinib, to cabozantinib in expand and tumor that XLXXX indications cost partners but XXX near-term footprint, clinical other therapy while in the the development opportunity coming with in to the some in this in are development

not therapy, for opportunities a with include different And again, different across and the plan cabozantinib looking lot see looking but project are lines do also an may to and And of I development various so combination of but think, in we cabozantinib indications. replace certainly partners indications, head-to-head to of we’re XLXXX’s that of array some study.

Andy Hsieh

the thoughts that to or you maybe, seeing any more stabilization with going one of maybe, the TKI going of And see you. kind if going the Thank for the when it be is back of P.J. kind would you’re are stabilize, dynamic on just necessary anticipating to some sort points wondering be with vaccine COVID-XX market, and Great. in like to impact inflection a near-term? your I’m that,

P.J. Haley

on COVID. market Yes. Thanks vis-à-vis specifically want too Andy. the the for question, I much TKI speculate to wouldn’t RCC,

been folks that you community, Community depending out see screening think, have impacts things do that’s but to influence normal feedback, patients’ the look you data, customer that back that anecdotally are geography, cetera, like may location, do starting et you things hear the just of journey. the think the these to when at from things follow-up tele-health published – on for there, put I of Oncology I get Association, the

we’re little forward, but think CABOMETYX very kind growth what’s the excited regards of forward regards Obviously, approval I with too think you really, of mentioned being just getting work the to through in with I about Mike the for looking -XER important go that, through ready pandemic. So system but much launch to oncology system. And of wouldn’t and I business the is speculate with ball broadly for to then bit anyone with kind think, for as crystal a we that really is the no approval. I in time, working those, and want that there’s to call can’t for take that driving and mentioned, us, the just this to

Andy Hsieh

Right. Yes, absolutely, yes.

answering Thanks Looking for questions. all forward my the that approval. to and insights all

Gisela Schwab

Andy. bet, You

Operator

come the of And next Cowen. line Werber from question our Yaron will with

Leo Wallen

everyone. for This Leo on Werber. Yaron Hi, is

Gisela Schwab

Hi.

Leo Wallen

Thanks the for first questions; have couple a cabo. my taking questions. regarding of I is

I’m trend seeing like second-line first-line of trends segments, such a to of any or are and RCC, terms quarter I’m in market the approval TKI. maybe, about terms in XXX. next if versus that how of COSMIC-XXX wondering just risk kind as categories versus risk would wondering the for in different mentioned just favorable guys specific different cool any You different of the the the and year you follow-up reverse just within you first-line I see data potential trend in -XER have trends different from Thanks. risk? or market question for RCC. first the potential RCC

P.J. Haley

it’s I’ll Leo, P.J. that first Hi, question. take Yes.

setting. is trends, in significant of XX% TKI what as see combination mentioned the I IO of the look something broadly, So, but is, is we’ve of the RCC, IO/TKI. XX% that of what say and terms setting combinations utilization else of they frontline and kind when frontline were. therapy, at I presented in the you Approximately, would market you for and

for those significant are in is I and well all which mentioned, an now, of of think we forward, -XER segments, the share favorable, for are get really see we growth, therapy the across second currently I as patients, who progressing vast kind -XER regards and With majority across clinical of what we our competing And therapy second have key potential line. groups, as all segment across CABOMETYX share approval. -XER in we retaining in poor get potentially we competitors. the intermediate from as current and So, second see risk competing of kind IO/TKI – opportunities line, doing see see the well across looking the pending it’s to certainly and getting line risk IO-based there, the market an to

as So potential we see forward. growth could look there again,

So, I about. to of just think broadly excited we’re potential -XER, the pending grow we’re extremely looking the at approval which

Leo Wallen

thanks. Okay,

are the a use or of versus it’s as you So, first-line decreasing more in dynamics, RCC same? trend IO/IO still of IO/TKI, maintained seeing like the of terms of

P.J. Haley

slides, got, bar look the you. of broken at a I mean you chart we’ve if one Yes. in got we’ve that out for

is or So, quarters. that’s slightly been we maintaining And what would currently. increasing IO/TKI last about the of XX% couple we’ve say, either I see first-line the as seen over

that the in of So, broadly that kind I marketplace. shows resonating think is really IO/TKI

there’s a the So, really I think that momentum potential to build opportunity in on with CABOMETYX -XER approval.

Leo Wallen

I see. Thanks.

So, wondering, XXX, will directory just identify through to that accelerated allow go any you path? indication you I’m if the regarding the potential

Gisela Schwab

question. Gisela. is for the This Thanks Yes.

point. this data think dependent. speculate entirely bit I point, And early will it’s a little this at at to this be

about compounds, more in the indications, as X So, expansion data we cohorts specific the the and data-driven incorporated Phase make learn then certainly we’ll have in decisions. a we examine study, and

Leo Wallen

Got it.

so you helpful. Thank much. very Okay. It’s

Gisela Schwab

Thanks, Leo.

Operator

from question next Guggenheim. our of Michael the with will line And Schmidt come

Michael Schmidt

my thanks prior questions. couple to and It’s since where of in afternoon, the taking presented. asthma a follow-up Good guys. been was a while questions. just Hey, now Maybe, little for data type -XER

of we while it’s your engagement, has regard, about feedback the feedback February. let from been you KOLs guidelines of combination the think has been wondering Just and wondering, physicians what a that what how inclusion level potential the rate in [indiscernible] in what and to also in to approval one should prior since now

P.J. Haley

this P.J. Hey, is Michael.

So, won’t kind ad NCC, to might and, I it, speculate do in just they of to to they of many wait see market I’ll a – I what positions. lot a mean, the second boards, research when with we’ve to also have and on done regards they and community feedback, just part, or regards significant and talked how that KOLs, academic goes. with we’ve of With conducted amount

well talking over we’re point. So, this at XXX physicians

combination I that think milligrams new very a that are looking these and looking is I efficacy patients can of doing this response combination profile really life it When survival XX think IO/TKI; kind physicians like, is it’s their and feedback to up impressive. both terms believe maintains a terms of and with getting experience daily their efficacy setting. relative they of agents in the that tolerability look increasing, at been totality separately. survival, gotten really be sort sampling in And combination kind of positive while it and and optimized at while that all you nice of terms fact progression-free with that best-in-class that quality sunitinib, flavor only a which of of dose sense that and of they’re and in objective and novel extremely life to in really it’s favorable for of, all the nivo at wrap quality overall really it’s of the rate, doubles here, this on this the use a build really of this viewing in in So, the we we’ve you and want they will data, safety improving really and

the So, I think team favorable, sort it��s both of to to across educate and go launch is person, to and in we’re get been entire and the and I out opportunity that the excited, forward ready virtually think on the very it board, data. just having there we’re looking

Michael Schmidt

guess, Tecentriq-Avastin are to Okay. from sway one purely efficacy frontline about and play potentially on the I Are the that the And approved cancer then differentiation how is it prescribe physicians other question? versus pending an that do COSMIC-XXX, combination study, other liver might factors potential obviously? you success, think combination, there

Mike Morrissey

as P.J. Mike, addressed Yes, that well.

have the study be get will data-dependent. we’ll obviously, to positive answer think a that I to and

a in well multiple XX% terms think, rapid I the that seeing data about XX%. things in those, in of setting think I the of atezo/bev first-line first-line, uptake sources, couple as already do combination seeing of to share we’re

So on – mechanism type and is have to a been option so over decade. depending a therapy opportunity backbone where like TKIs that with much it’ll novel for very we’ll of the tumor I differentiate of action. great data this think option, IO/TKI IO/bev be said, and an renal, of instead a

where places, data. So, from appropriate I are bevacizumab an think what large terms those think safety that’s well second-line with have interim progressing criteria, standpoint in and there’s in that physicians then experience setting where there, for – potential some have a that see do will there. growth first-line the we’ll into an slight certainly, potential represents therapy think we’ll to the perhaps nuances inclusion but regards and patients wait HCC. on the a we certain I be we’ll about be opportunity IO-based of And in of obviously, to we’ll really – given opportunity patients want – But the advantage potentially, profile, the to

Michael Schmidt

or And one, for maybe then Peter Gisela. Okay.

might XLXXX, clinical the advantage be translate potentially that pushing where guess a example. and a and binding to that as a to the dosing to potential and certain XLXXX more characteristics would Is molecule of mainly might to on so profile? differentiated advantageously that relative safety expect positioned or CABOMETYX Just or into higher efficacy it for able CABOMETYX indications similar there shorter how I maybe result a half-life, that of given further, are one

Gisela Schwab

Gisela. Yes, question. this for the is Thank you

long it’s think a longer. half-life as [indiscernible] differentiated cabozantinib events the depends could the quickly I profiles? worth earlier, half-life management more is, tolerability time of could the and translate that question key is improved how event does in on management it’s here the explained And shorter into key Peter is adverse subside and be

So be events quickly. and adverse that would could sit be side expected to shorter more

peri-surgery profile be that other of that thinking things it’s about to like that fashion also wound to notable shorter VEGFR. as and well an in could to could so have kept targets in where half-life in into and in as half-life course, safety when you terms it TKI important always would if be dosing the improved indications advantages when user-friendly administration, more translate mind longer potentially will be of that or build resulting pleased a TKI And healing

this a specific one half-life, be including But we indications can compound benefit. would that And also as such diversified just be that’s so XLXXX mentioned. have here. of General, a a where a as that and broad could indication potentially it’s setting, very development, shorter a

Michael Schmidt

Okay. Thank much. you so

Gisela Schwab

you, Thank Michael.

Operator

the Our with from Capital next question line Kennen will come of MacKay RBC Markets.

Kennen MacKay

already of about drives about that you. hoping to be of Thank essentially, approved, the question. specifically team the eyes combos the the bit TKI versus cabo/nivo in cabo/nivo Thanks choose could was for differentiated I other taking the checkpoint of physicians -XER edge what’s combinations. profile that little how other in a are comment the going any would that to over physicians be CheckMate some the

P.J. Haley

and hi Yes, Ken, this that. is I’ll take P.J.

earlier, the broadly of compelling and this I from kind think really for data to referring was we’ve heard market and in are research I As KOLs.

the only and but it’s combination that’s only objective doubling only of while first rate only all, IO/TKI, survival. – think, the the PFS improving not I response

to data, Furthermore, safety to you discontinuation when physicians So, look of really clinical maintaining the despite profile, at unique the and with all And other that low of I to, efficacy you think very right, talked is IO/TKI. look totality a the look good of second dose. EU the and good that rate the quality life compelling. at milligram data, tolerability benefit which it’s the life then if relative drug XX we’ve rate, that’s I think quality providing really adding

good compelling for So, feedback I really really heard we’ve think that’s on physicians and it.

So, I regards and of position favorable, with broadly any poor, opportunity intermediate groups, across think successfully it that and gives competitors. to a to us potential risk lot

Mike Morrissey

a best-in-class four lot discussion terms and really on boards research on would consistent Mike. the as of people definitely that towards very lot website the And it’s lot I’d listen question, to KOLs still with great, are very take feedback, still very Yes, think great they of back really discussion competitive was in hi, done There had tier of perspective top we of in refer ad our presentation there not only a it’s to a research, combination, blinded a is and also that kind and is analyst That’s veteran but been that September market that. of Ken, presentation market post recommend ESMO good online. a a a we’ve great why instead you there, of this well. back

Kennen MacKay

Thanks, Mike. Thanks, P.J.

Gisela Schwab

you, Thank Ken.

Operator

going of to with the question is Messer Chad line next from Company. & our And come Needham

Duane Kailas

for Duane Thanks everyone. in. this squeezing And for is Hello, Chad. me

in revisited question challenges or development? to here certain cabo one from going that are with us. face indications XLXXX Just be Are

Gisela Schwab

Gisela. This is

we at type. are that the we Just of it the XLXXX lines across therapy and certainly different development of of new plan. lines can and indications, And where different that cabozantinib. and developed therapy, various to lines areas profile in to But tumor also its adjuvant back different indications certainly compound. now broader different given combinations see adjuvant plan the earlier for the opportunity in of with commercialized We target there go been development the been cabozantinib see opportunity looking a therapy haven’t within has explored including combinations be where

build development are cabozantinib more as wide we opportunity so array the really opportunities. plan, of with the on from this to development broadly And cabozantinib and a viewing plan an

Duane Kailas

taking on all question for you the right. Thank All and congratulations the progress.

Gisela Schwab

Thank you, Gill.

Operator

will question Stephen our with line of Stifel. from And next the come Willey

Stephen Willey

squeezing me for thanks Yes, in.

to I regarding those not know you mentioned in five are but So have I that assuming providing, just a to I guys whether of that and on can relative had other inputs or maybe rate majority had spoke maybe quick kind or were year be, you the no, guess just that run P.J. that number, to point. that what question. treatment there little at or expect the you you’re that combo be to I maybe assuming approved a think, end you and share extent? you Mike, I ICI/TKI guys competitors you XXXX those guidance think market bit combos you mentioned, guys a say, yes just know to duration

Mike Morrissey

competitive from it’s if conservative We a very view. share share Mike. will, terms point you it’s data if of that say market market it’s majority offline give ledge, Steve, Yes. share I arguably very to would of a of large a not, we’re level estimate don’t we want market on in either. comparable. But get we’re that’s not certainly going assuming a, a

So, that we’re in here, of a a upon some growth we’re approximately view those the PFS doubling leaving a cabo conservative based very duration is obviously, share, as data driver and other treatment, market taking, of But the of rate. XXX indication. strong for I of run even think in activities well, for that of upside conservative terms expectation beyond

Stephen Willey

filing. – see quickly press that No, I guys kind on is, guess just yes, Okay. this any And, interim you of the we COSMIC-XXX. real then expect within know just in didn’t. Or release? to guess, to I we’re going we there’s something going stay that we should a are data, threshold just – a be coming read was quarter to hit are where I

We’re going forward.

Mike Morrissey

Yes. study. our It’s

say we it. say and when we have with what flexibility So, more we

I we’ll of put that of of some I’m in And press give mean, to top-line here, release but kind people the uber that sense remains some data seen. results. be do level we normally So, assuming to

tuned. stay So,

Stephen Willey

right. helpful. That’s you. Thank All

Gisela Schwab

Steve. Thanks,

Operator

from come will of question Choi with next Goldman our And Sachs. line Paul the

Charlie Ferranti

just so previously on had have for Hi for our everyone. this X quick Thanks cell much Phase cohort Paul. cancer, point. a that This and there taking drop for lung the XLXXX is to question I Charlie study. noticed indication to that I at questions. cohort edited Ferranti a was designated that appears non-small been on

And I using so I’m to just I because evolved approach wondering, presentation listed somehow that terms on XLXXX, as the Slide, has think your still in potential indication on NSCLC maybe see thinking XX target. you of of how this a is want it

very much. thinking lung So, wondering you’re at Thank how this just about you point?

Gisela Schwab

are process various of as including anything… our in a and variety cancer is XLXXX develop and interest and a a our is Lung lung Charlie Absolutely. and potential combination cancer we a indication fittings as as plans. containing certainly different and forward we go we Hey, in approaches certainly still backbone, thought

Charlie Ferranti

for you. it That’s much. so you Thank Thank tonight.

Operator

Susan turn closing Hubbard now comments. I’ll for conference the you. to Thank over

Susan Hubbard

able joining have Great. us Thank your we may you were Holly. calls today. on any address call. certainly thank with today’s you, for additional And all you not We to follow-up welcome that questions

Operator

on joining participation. us follow-up for thank And all walked your your calls today. Thank and We appreciate you. you we

You may disconnect. now

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.